Compare Jabil Inc (JBL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Novo Nordisk A/S — how do they compare? Jabil Inc trades at $366 (market cap $37.37B), while Novo Nordisk A/S trades at $46.32 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 5.6× Jabil Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| JBL | NVO | |
|---|---|---|
Market Cap | $37.37B | $207.85B |
Sector | Technology | Health |
52-Week High | $385.50 | $63.98 |
52-Week Low | $192.49 | $35.29 |
Enterprise Value | $39.90B | $222.55B |
Dividend Yield | 0.09% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL stock trades at $366.16, up 8.77% in the last session, reflecting strong momentum driven by AI infrastructure demand. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.16 exceeding the $3.10 forecast. Technical indicators show a bullish trend with the stock approaching resistance near $371, while fundamentals reveal solid revenue growth projections from $29.8B in 2025 to $33.6B in 2026.
JBL presents compelling growth potential as an AI infrastructure play with projected revenue exceeding $20B by 2027, though elevated P/E of 44.63 and thin net margins of 2.57% warrant caution. Analyst consensus targets $448.29 (22% upside) with balanced buy/hold ratings. Key risks include execution challenges in scaling AI operations and competitive pressures in electronics manufacturing services.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
